	US 12,246,063 B2
	Immunogen providing an extended protective lifetime against respiratory syncytial virus (RSV) and vaccines thereof
Milton J. Friedman, Alameda, CA (US); and Lawrence M. Kauvar, San Francisco, CA (US)
Assigned to Trellis Bioscience, Inc., Redwood City, CA (US)
Filed by Trellis Bioscience, LLC, Redwood City, CA (US)
Filed on Feb. 5, 2021, as Appl. No. 17/168,553.
Application 17/168,553 is a continuation of application No. PCT/US2019/045775, filed on Aug. 8, 2019.
Claims priority of provisional application 62/716,184, filed on Aug. 8, 2018.
Prior Publication US 2021/0268096 A1, Sep. 2, 2021
Int. Cl. A61K 39/12 (2006.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01)

CPC A61K 39/12 (2013.01) [A61P 31/14 (2018.01); A61K 2039/545 (2013.01); A61K 2039/6056 (2013.01)]

17 Claims

1. An immunogen providing an extended protective lifetime against respiratory syncytial virus (RSV) comprising a complex formed by an RSV G protein or peptidomimetic, wherein said RSV G protein includes a central conserved domain (CCD) with a monoclonal antibody or antigen-binding fragment thereof that blocks interaction of the recombinant RSV G protein with host receptor CX3CR1.